FINNENCE▪
00:00:00 UTCSYS ONLINE
FINNENCE ▪ THE WIRE FILE

THE WIRE · № 71555

Company■ Unclear/unknown

New Phase 3 trial: A Phase 3 Study of Povorcitinib Phosphate in Chinese Adults With Nonsegmental Vitiligo — Dermavon Holdings Limited

KINDCompany
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES2
STORY SIZESTANDALONE
FIRST SEEN2026-10-08 12:00 UTC
LAST UPDATE2026-10-08 12:00 UTC
STATEactive

01 THE MACHINE READ

WHY IT MATTERS.

A China-focused vitiligo Phase 3 adds to the dermatology pipeline but has no stated readout.

Early-stage vitiligo trial in Chinese adults
CATALYST TO WATCH

First patient enrollment

MAIN RISK

Not-yet-recruiting status slips

FULL DISPATCH

Sponsor: Dermavon Holdings Limited; Status: Not Yet Recruiting; Conditions: NonSegmental Vitiligo; Interventions: Povorcitinib phosphate, Placebo; Enrollment: 174 (estimated); First posted: 2026-10-08; NCT: NCT07865312

02 THE STORY SO FAR

THE RECORD, IN ORDER.

STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.

03 WHO'S INVOLVED

ENTITIES ON FILE.

AFFECTEDChina
AFFECTEDHealthcare

04 RECEIPTS

THE SOURCE RECORD.

1 SOURCES CONFIRMED
№ 01clinicaltrialsclinicaltrials.gov · PRIMARY2026-10-08 12:00 UTCOPEN RECEIPT →

05 PROPAGATION

WHAT THIS TOUCHES.

KEEP READING THE MACHINE

OPEN THE MACHINE →THE PREDICTION LEDGER →

Summaries are generated and may contain errors — every claim links its sources.